Olgram.com is a biopharmaceutical startup that focuses on the development of innovative drugs and therapies for immune diseases and chronic infections. The company's primary market is the healthcare and pharmaceutical industry, specifically in the areas of immunology and infectiology.

Olgram's unique selling proposition is its use of molecules derived from algae to develop new drugs. These drugs are designed to cure immune diseases and infections by destroying the bacteria that cause relapses. This approach is particularly relevant for patients suffering from chronic infections and immune diseases resulting from traumatic brain injuries.

In addition to its healthcare focus, Olgram also has a strong commitment to environmental sustainability. The company's industrial process for creating some of its drug candidates is designed to absorb significant amounts of CO2, thus contributing to the fight against climate change.

The company operates on a business model that involves the development and commercialization of its proprietary drugs and therapies. Revenue is generated through the sale of these products to healthcare providers and institutions.

Olgram's team comprises international experts in research, drug development, and pharmaceutical and industrial successes. This diverse and complementary team is instrumental in driving the company's research and development efforts.

In summary, Olgram is a promising biopharmaceutical startup that combines innovative healthcare solutions with a strong commitment to environmental sustainability.

Keywords: Biopharmaceutical, Immune Diseases, Chronic Infections, Algae-derived Molecules, Traumatic Brain Injuries, CO2 Absorption, Environmental Sustainability, Drug Development, Healthcare Industry, Research and Development.